Highlights Repligen Corporation

Equities

RGEN

US7599161095

Real-time Estimate Cboe BZX Other stock markets 11:32:18 2024-04-30 am EDT			5-day change	1st Jan Change
166.7 ^USD	+0.36%		-2.60%	-7.22%

Apr. 08	RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating	MT
Mar. 20	Transcript : Repligen Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 03:00 PM

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Repligen Q4 Adjusted Earnings, Revenue Decline; Issues 2024 Guidance; Shares Fall Premarket	Feb. 21	MT
Sartorius falls - outlook from Repligen disappointed	Feb. 21	DP
(RGEN) REPLIGEN CORPORATION Expects Fiscal Year 2024 EPS Range $1.42 - $1.49	Feb. 21	MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q4 Revenue $155.7M, vs. Street Est of $156.3M	Feb. 21	MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q4 EPS $0.33, vs. Street Est of $0.34	Feb. 21	MT
Repligen Corporation Provides Earnings Guidance for the Year 2024	Feb. 21	CI
Repligen Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Repligen Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
Repligen to Seek Acquisitions	Dec. 07	CI
Repligen Corporation Launches TangenX®? SC as First-To-Market Holder-Free Self-Contained TFF Device	Nov. 02	CI
Repligen Q3 Adjusted Earnings, Revenue Fall; 2023 Adjusted EPS Outlook Lowered, Revenue Guidance Revised	23-10-31	MT
(RGEN) REPLIGEN CORPORATION Sees Fiscal Year 2023 EPS Range $1.70 - $1.76	23-10-31	MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q3 Revenue $141.2M, vs. Street Est of $140.6M	23-10-31	MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Posts Q3 EPS $0.23, vs. Street Est of $0.16	23-10-31	MT
Repligen Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2023	23-10-31	CI
Repligen Corporation acquired Metenova AB for $173 million.	23-10-01	CI
Repligen to Acquire Fluid Management Company Metenova	23-09-26	MT
Repligen Corporation entered into a definitive agreement to acquire Metenova AB for $173 million.	23-09-25	CI
Repligen Partners With Sartorius to Launch Integrated Bioreactor System	23-08-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Repligen Corporation

Equities

RGEN

US7599161095

Highlights

Filters